A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults
A Randomized, Open-label, 6-sequence, 3-period Crossover Clinical Trial to Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adult Volunteers.
1 other identifier
interventional
30
1 country
1
Brief Summary
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started Aug 2026
Shorter than P25 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 16, 2026
CompletedFirst Posted
Study publicly available on registry
July 21, 2026
CompletedStudy Start
First participant enrolled
August 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2026
July 27, 2026
July 1, 2026
3 months
July 16, 2026
July 24, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percent of Time With Gastric pH ≥4 During the 24-hour Interval After the 7th Dose
From pre-dose (0h) on Day 7 to 24 hours post-dose on Day 7 of each treatment period (Period 1: Day 7-Day 8; Period 2: Day 28-Day 29; Period 3: Day 49-Day 50)
Study Arms (6)
Arm A(Vonoprazan, Fexuprazan, Vonoprazan)
EXPERIMENTALParticipants receive AD-234 - AD-2341-AD-2342
Arm B(Vonoprazan, Vonoprazan, Fexuprazan)
EXPERIMENTALParticipants receive AD-234 - AD-2342- AD-2341
Arm C(Fexuprazan, Vonoprazan, Vonoprazan)
EXPERIMENTALParticipants receive AD-2341-AD-234-AD-2342
Arm D(Fexuprazan, Vonoprazan, Vonoprazan)
EXPERIMENTALParticipants receive AD-2341-AD-2342-AD-234
Arm E(Vonoprazan, Vonoprazan, Fexuprazan)
EXPERIMENTALParticipants receive AD-2342 -AD-234-AD-2341
Arm F(Vonoprazan, Fexuprazan, Vonoprazan)
EXPERIMENTALParticipants receive AD-2342-AD-2341-AD-234
Interventions
AD-2341 tablet administered orally
AD-2342 tablet administered orally
AD-234 tablet administered orally
Eligibility Criteria
You may qualify if:
- Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening
- Body weight between 50.0 kg and 90.0 kg, inclusive, and body mass index (BMI) between 18.5 kg/m\^2 and 29.9 kg/m\^2, inclusive, at the time of screening (BMI = weight \[kg\] / height \[m\]\^2)
- For female participants: not pregnant, not breastfeeding, or surgically sterile (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Addpharma Inc.lead
Study Sites (1)
Seoul National University Hospital, Seoul,
Seoul, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 16, 2026
First Posted
July 21, 2026
Study Start
August 1, 2026
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
November 1, 2026
Last Updated
July 27, 2026
Record last verified: 2026-07